EPI-CAN new generation of liquid biopsy biomarkers

EPI-CAN brings new generation of epigenetic biomarkers for clinical applications.

Research

Our preliminary research results are available from:

Early cancer diagnosis increases 4 times survival rate*

Early cancer diagnostic tests based on liquid biopsy concept, not only saves lives, but also bring significant reductions of the cost of cancer management in the health care systems.

Learn More

*Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015. Data on file GA-2021-004.

What is
liquid biopsy?

A liquid biopsy is a blood-based diagnostic test that detects cancer DNA circulating in the bloodstream, referred to as “circulating tumor DNA” or more generally "cell-free DNA".

About EPI-CAN

Spin-off based on patent pending technology, developed at The Independent Clinical Epignetic Laboratory, Pomeranian Medical University in Szczecin, Poland.

Proof-of-concept

We have proofed that our solution can be used to detect and classify a cancer using liquid biopsy. Soon to be published in peer-review journal.

Milestones

Scroll to learn about our project’s journey

YEAR

2021

First grant

In 2021 we received the first grant to perform proof-of-concept of our innovation.

YEAR

2022

First liquid-biopsy test

In 2022 we successfully extracted and classify cell-free DNA samples from blood of cancer and healthy patients using our technology.

EPI-CAN TEAM

Jan

Bińkowski

Co-founder

Tomasz K.

Wojdacz

Co-founder, PhD, MBA